Search
Eptinezumab
go.drugbank.com/drugs/DB14040ApprovedInvestigational[F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]
Sulopenem etzadroxil
go.drugbank.com/drugs/DB16335ApprovedInvestigational[L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.
Nadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922] … [L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and
Cortisone acetate
go.drugbank.com/drugs/DB01380ApprovedInvestigational[A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487]
Fusidic acid
go.drugbank.com/drugs/DB02703ApprovedInvestigationalAn antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in sys...
Mixtures: M-FURO FA %0.1 + %2 KREM, 30 GMyristic acid
go.drugbank.com/drugs/DB08231InvestigationalMixtures: Jayjun Real Water Shining Vita Cleansing Foa M, Jayjun Real Water Brightening Black Mask Step 01 Real Water Cleansing Foa MDinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalIt is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.
Categories: N-Calcium Channel Receptor AntagonistsBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331] … [A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the